PepTalk’s Antibody Discovery & Engineering pipeline offers a forum for protein scientists who are working to quickly and efficiently discover and develop differentiated biotherapeutics for unmet medical needs. For 2024, the pipeline presents the two-part Intelligent Antibody Discovery program, with Part 1 focused on methods and technologies that offer predictive insight into function, binding and developability in support of improved candidate selection, and Part 2 considering current progress in integrating machine learning into discovery and engineering workflows.
January 16-17
Intelligent Antibody Discovery: Part One
January 18-19
Intelligent Antibody Discovery: Part Two
KEYNOTE & FEATURED PRESENTATIONS:
Predicting Antibody Developability at the Discovery Stage
Peter M. Tessier, PhD, Albert M. Mattocks Professor, Pharmaceutical Sciences & Chemical Engineering, University of Michigan
Better Medicines, Created Rapidly through de novo Protein Design
Chris Bahl, PhD, CSO and Co-Founder, AI Proteins
De novo Design of Miniprotein Ligand Scaffolds for Molecularly Targeted Therapy
Benjamin J. Hackel, PhD, Professor, Chemical Engineering & Materials Science, University of Minnesota
If you are working in the following areas join the PepTalk community:
- Antibody Discovery
- Antibody Engineering
- Antibody Technologies
- Biologics Development
- Biotherapeutics Development
- Cellular Engineering
- Development
- Protein Engineering
- Protein Sciences
- Regulatory Affairs
- Research